{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:25:19Z","timestamp":1782051919108,"version":"3.54.5"},"reference-count":89,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti\u2010tumor necrosis factor\u2010\u03b1 antibodies, became available in the field of dermatology in 2010, followed by ustekinumab, an anti\u2010interleukin (IL)\u201012\/IL\u201023p40 antibody, which was launched in Japan in 2011. Since 2015, three IL\u201017 inhibitors of secukinumab and ixekizumab, anti\u2010IL\u201017A antibodies, and brodalumab, an anti\u2010IL\u201017 receptor antibody, and two anti\u2010IL\u201023p19 antibodies of guselkumab and risankizumab, have also been launched. It is important for physicians to select appropriate biologic therapy for each psoriatic patient after due consideration of disease factors, treatment factors and patient background factors, sharing such information with patients. The following can be listed as points to be considered for the selection of biologics: drug effects (e.g. strength of effectiveness, time to onset of effectiveness, effectiveness against arthritis, primary failure, secondary failure), safety (e.g. infections, administration\u2010related reactions and relationships with other comorbidities), convenience for patients (e.g. hospital visit intervals, self\u2010injection, maintenance therapy at clinics, feasibility of drug discontinuation\/re\u2010administration) and payment (medical costs) borne by patients. This guidance has been prepared with the aim of allowing dermatologists experienced in the treatment of psoriasis to use biologics appropriately according to the circumstances of individual patients after consideration of the above\u2010mentioned factors.<\/jats:p>","DOI":"10.1111\/1346-8138.15196","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T04:10:06Z","timestamp":1578543006000},"page":"201-222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Japanese guidance for use of biologics for psoriasis (the 2019 version)"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"first","affiliation":[{"name":"Department of Dermatology Nippon Medical School Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Terui","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nihon University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-0216","authenticated-orcid":false,"given":"Shigetoshi","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kochi Medical School Kochi University Kochi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine Fukuoka University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3182","authenticated-orcid":false,"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-1803","authenticated-orcid":false,"given":"Mayumi","family":"Komine","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jichi Medical University Shimotsuke Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Etoh","sequence":"additional","affiliation":[{"name":"Division of Dermatology Tokyo Postal Services Agency Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Division of Dermatology NTT Medical Center Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Torii","sequence":"additional","affiliation":[{"name":"Division of Dermatology Tokyo Yamate Medical Center Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8863-9428","authenticated-orcid":false,"given":"Masatoshi","family":"Abe","sequence":"additional","affiliation":[{"name":"Kojinkai Sapporo Skin Clinic Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Research Division for Development of Anti\u2010Infective Agents Faculty of Medical Science and Welfare Tohoku Bunka Gakuen University Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yotsuyanagi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Advanced Clinical Research Center Institute of Medical Science The University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jichi Medical University Shimotsuke Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Biologics Review Committee of the Japanese Dermatological Association for Psoriasis: Chair: Mamitaro Ohtsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"163","article-title":"The guideline and safety manual for use of anti\u2010TNF\u2010\u03b1 agents in psoriasis","volume":"120","author":"Ohtsuki M","year":"2010","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_9_3_1","first-page":"1561","article-title":"Guideline and safety manual for use of biologic agents in psoriasis (the 2011 version)","volume":"121","author":"Ohtsuki M","year":"2011","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12239"},{"key":"e_1_2_9_5_1","unstructured":"Precautions for use of secukinumab. Website of the Japanese Dermatological Association."},{"key":"e_1_2_9_6_1","unstructured":"For use of infliximab BS. Website of the Japanese Dermatological Association."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14523"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22805"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.04.014"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00971.x"},{"key":"e_1_2_9_15_1","first-page":"1","article-title":"Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post\u2010marketing surveillance","volume":"42","author":"Torii H","year":"2015","journal-title":"J Dermatol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13698"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04515.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13409"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12046"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204741"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12668"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.011"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13911"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_9_43_1","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double\u2010blind, phase III FUTURE 5 study","volume":"77","author":"Mease P","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170429"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.10.009"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13785"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14504"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14294"},{"key":"e_1_2_9_62_1","first-page":"826","article-title":"Long\u2010term efficacy of guselkumab for the treatment of moderate\u2010to\u2010severe psoriasis: results from the phase 3 VOYAGE 1 trial through two years","volume":"17","author":"Christopher EM","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14941"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16102"},{"key":"e_1_2_9_68_1","first-page":"242","article-title":"Current severe psoriasis and the rule of tens","volume":"39","author":"Finlay AY","year":"2012","journal-title":"Br J Dermatol"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1987.tb01844.x"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055"},{"issue":"2","key":"e_1_2_9_72_1","first-page":"5","article-title":"European S3\u2010guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana D","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13354"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09505.x"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15665"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12118"},{"key":"e_1_2_9_77_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/ddg.13516","article-title":"S3 guideline for the treatment of psoriasis vulgaris, update \u2013 short version part 1 \u2013 systemic treatment","volume":"16","author":"Nast A","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1294727"},{"key":"e_1_2_9_81_1","first-page":"497","article-title":"Treatment guidelines for latent tuberculosis infection","volume":"88","author":"The Prevention Committee and the Treatment Committee of the Japanese Society for Tuberculosis","year":"2013","journal-title":"Kekkaku"},{"key":"e_1_2_9_82_1","unstructured":"The Japan College of Rheumatology Review Committee for Anti\u2010Rheumatic Disease Drugs.Guideline for TNF inhibitor therapy for rheumatoid arthritis (RA) (revised 2018 version). Website of the Japan College of Rheumatology 2018."},{"key":"e_1_2_9_83_1","unstructured":"The Japan Society of Hepatology (JSH) Drafting Committee for Hepatitis Management.JSH guidelines for the management of hepatitis B virus infection (3rd version): document 3 guidelines for preventing hepatitis B due to immunosuppressive therapy or chemotherapy. Website of the JSH 2017."},{"key":"e_1_2_9_84_1","first-page":"356","article-title":"Prevention, diagnosis and treatment of tuberculosis and non\u2010tuberculous Mycobacteriosis, in patients with rheumatoid arthritis","volume":"37","author":"Watanabe A","year":"2007","journal-title":"Rheumatology"},{"key":"e_1_2_9_85_1","unstructured":"The Japanese Respiratory Society Committee.Consensus statements for medical practice: biological agents and lung disease.Tokyo:Kokuseido Co. Ltd 2014;59\u201369."},{"key":"e_1_2_9_86_1","first-page":"568","article-title":"Biologics and infections\/chemotherapy","volume":"65","author":"Watanabe A","year":"2017","journal-title":"Jpn J Chemotherapy"},{"key":"e_1_2_9_87_1","unstructured":"The Japan College of Rheumatology Subcommittee for methotrexate (MTX) Treatment Guideline Formulation.Guideline for MTX therapy for rheumatoid arthritis (revised 2016 version). Website of the Japan College of Rheumatology 2016."},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11015.x"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205554"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416631328"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.15196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.15196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:30:38Z","timestamp":1694046638000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.15196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/1346-8138.15196"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.15196","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"2019-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}